This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neumann, E. Articles by Seliger, B. Search for Related Content PubMed PubMed Citation Articles by Neumann, E. Articles by Seliger, B.

Heterogeneous Expression of the Tumor-associated Antigens RAGE-1, PRAME, and Glycoprotein 75 in Human Renal Cell Carcinoma: Candidates for T-Cell-based Immunotherapies?¹

The Johannes Gutenberg-Universität, III. Medizinische Klinik, 55131 Mainz [E. N., A. E., J. D., C. H., B. S.]; Klinikum Wuppertal, Institut für Pathologie, 42283 Wuppertal [S. S.]; and Nordwest Krankenhaus, II. Medizinische Klinik, 60488 Frankfurt [E. J.], Germany

It has recently been shown that tumor-associated antigens (TAAs) can evoke tumor-specific T-cell-defined immune responses in cancer patients, thereby offering the possibility of treating patients with such antigens. To develop T-cell-based immunotherapeutic approaches for renal cell carcinoma (RCC), we studied the mRNA expression profile of the TAAs RAGE-1, tyrosinase, MAGE-1, MAGE-2, NY-ESO-1, Melan-A/MART-1, glycoprotein (gp) 75, gp100, ß-catenin, PRAME, and MUM-1 in 14 human RCC cell lines and in tissue specimens of 37 primary RCCs, 2 related metastases, and 33 specimens of normal renal epithelium. Reverse transcription-PCR was performed with TAA-reactive primers, and the specificity of the PCR products was confirmed by Southern blot and/or direct sequencing. PRAME (10 of 14 cell lines), RAGE-1 (7 of 14 cell lines), and gp75 (4 of 14 cell lines) antigens were expressed in a high percentage of RCC cell lines, although the level of TAA expression varied among the different RCC cell lines. However, low levels of TAA expression in RCC cells are sufficient for recognition by TAA-specific CTLs. Transcription of tyrosinase, Melan-A/MART-1, MAGE-1, MAGE-2, NY-ESO-1, gp100, ß-catenin, and MUM-1 was not detected in any RCC cell line. Approximately 50% of surgically removed neoplasias expressed at least one TAA. RAGE-1 mRNA expression was found in 8 of 39 (21%) RCC samples, PRAME mRNA expression was found in 15 of 39 (40%) RCC samples, and gp75 mRNA expression was found in 4 of 39 (11%) RCC samples, but the expression levels of these TAAs were heterogeneous in the different RCC lesions. One RCC specimen expressed MAGE-2, whereas transcription was not detected in any RCC specimen for MAGE-1, NY-ESO-1, tyrosinase, Melan-A/MART-1, gp100, ß-catenin, and MUM-1. The normal kidney epithelium samples were negative for any TAA tested. Thus, RAGE-1, PRAME, and gp75 expression is found with a different frequency in surgically removed lesions and in RCC cell lines, suggesting that a subgroup of RCC patients could be selected for immunotherapeutic strategies that may benefit from immunization against the RAGE-1, gp75, and/or PRAME antigens. However, additional targets for T-cell-based immunotherapy of RCC have yet to be identified.

¹ Supported by the Deutsche Forschungsgemeinschaft, Grant SFB432 A5 (to B. S.), the Boehringer Ingelheim Fond (C. H. and B. S.), and Grant 93.038.2 from the Sander Foundation (to J. D.).

² To whom requests for reprints should be addressed, at Johannes Gutenberg-Universität, III. Medizinische Klinik, Langenbeckstrasse 1, 55101 Mainz, Germay. Phone: 49-6131-176760/173965; Fax: 49-6131-176678.

Received 12/ 1/97. Accepted 7/30/98.

This article has been cited by other articles:

				C. Santamaria, M. C. Chillon, R. Garcia-Sanz, A. Balanzategui, M. E. Sarasquete, M. Alcoceba, F. Ramos, T. Bernal, J. A. Queizan, M. J. Penarrubia, et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia Haematologica, December 1, 2008; 93(12): 1797 - 1805. [Abstract] [Full Text] [PDF]

				E. Sato, T. Torigoe, Y. Hirohashi, H. Kitamura, T. Tanaka, I. Honma, H. Asanuma, K. Harada, H. Takasu, N. Masumori, et al. Identification of an Immunogenic CTL Epitope of HIFPH3 for Immunotherapy of Renal Cell Carcinoma Clin. Cancer Res., November 1, 2008; 14(21): 6916 - 6923. [Abstract] [Full Text] [PDF]

				M. Garg, D. Kanojia, A. Khosla, N. Dudha, S. Sati, D. Chaurasiya, N. Jagadish, A. Seth, R. Kumar, S. Gupta, et al. Sperm-Associated Antigen 9 Is Associated With Tumor Growth, Migration, and Invasion in Renal Cell Carcinoma Cancer Res., October 15, 2008; 68(20): 8240 - 8248. [Abstract] [Full Text] [PDF]

				M. T. Epping and R. Bernards A Causal Role for the Human Tumor Antigen Preferentially Expressed Antigen of Melanoma in Cancer. Cancer Res., November 15, 2006; 66(22): 10639 - 10642. [Abstract] [Full Text] [PDF]

				M. Meissner, T. E. Reichert, M. Kunkel, W. Gooding, T. L. Whiteside, S. Ferrone, and B. Seliger Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome Clin. Cancer Res., April 1, 2005; 11(7): 2552 - 2560. [Abstract] [Full Text] [PDF]

				T. Nakatsura, H. Komori, T. Kubo, Y. Yoshitake, S. Senju, T. Katagiri, Y. Furukawa, M. Ogawa, Y. Nakamura, and Y. Nishimura Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice Clin. Cancer Res., December 15, 2004; 10(24): 8630 - 8640. [Abstract] [Full Text] [PDF]

				D. Avigan Dendritic Cell-Tumor Fusion Vaccines for Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6347S - 6352S. [Abstract] [Full Text] [PDF]

				A. Oberthuer, B. Hero, R. Spitz, F. Berthold, and M. Fischer The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome Clin. Cancer Res., July 1, 2004; 10(13): 4307 - 4313. [Abstract] [Full Text] [PDF]

				H. Mukouyama, N. K. Janzen, J. M. Hernandez, J. S. Lam, R. Caliliw, A. Y. Wang, R. A. Figlin, A. S. Belldegrun, and G. Zeng Generation of Kidney Cancer-Specific Antitumor Immune Responses Using Peripheral Blood Monocytes Transduced With a Recombinant Adenovirus Encoding Carbonic Anhydrase 9 Clin. Cancer Res., February 15, 2004; 10(4): 1421 - 1429. [Abstract] [Full Text] [PDF]

				L. Molto, P. Rayman, E. Paszkiewicz-Kozik, M. Thornton, L. Reese, J. C. Thomas, T. Das, D. Kudo, R. Bukowski, J. Finke, et al. The Bcl-2 Transgene Protects T Cells from Renal Cell Carcinoma-mediated Apoptosis Clin. Cancer Res., September 15, 2003; 9(11): 4060 - 4068. [Abstract] [Full Text] [PDF]

				M. Maio, S. Coral, L. Sigalotti, R. Elisei, C. Romei, G. Rossi, E. Cortini, F. Colizzi, G. Fenzi, M. Altomonte, et al. Analysis of Cancer/Testis Antigens in Sporadic Medullary Thyroid Carcinoma: Expression and Humoral Response to NY-ESO-1 J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 748 - 754. [Abstract] [Full Text] [PDF]

				S. Coral, L. Sigalotti, M. Altomonte, A. Engelsberg, F. Colizzi, I. Cattarossi, E. Maraskovsky, E. Jager, B. Seliger, and M. Maio 5-aza-2'-Deoxycytidine-induced Expression of Functional Cancer Testis Antigens in Human Renal Cell Carcinoma: Immunotherapeutic Implications Clin. Cancer Res., August 1, 2002; 8(8): 2690 - 2695. [Abstract] [Full Text] [PDF]

				K.-i. Hanada, D. M. Perry-Lalley, G. A. Ohnmacht, M. P. Bettinotti, and J. C. Yang Identification of Fibroblast Growth Factor-5 as an Overexpressed Antigen in Multiple Human Adenocarcinomas Cancer Res., July 1, 2001; 61(14): 5511 - 5516. [Abstract] [Full Text] [PDF]

				B. Seliger, U. Wollscheid, F. Momburg, T. Blankenstein, and C. Huber Characterization of the Major Histocompatibility Complex Class I Deficiencies in B16 Melanoma Cells Cancer Res., February 1, 2001; 61(3): 1095 - 1099. [Abstract] [Full Text]

				J. H. Kessler, N. J. Beekman, S. A. Bres-Vloemans, P. Verdijk, P. A. van Veelen, A. M. Kloosterman-Joosten, D. C.J. Vissers, G. J.A. ten Bosch, M. G.D. Kester, A. Sijts, et al. Efficient Identification of Novel Hla-A*0201-Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis J. Exp. Med., January 1, 2001; 193(1): 73 - 88. [Abstract] [Full Text] [PDF]

				P. Rawson, I. F. Hermans, S. P. Huck, J. M. Roberts, H. Pircher, and F. Ronchese Immunotherapy with Dendritic Cells and Tumor Major Histocompatibility Complex Class I-derived Peptides Requires a High Density of Antigen on Tumor Cells Cancer Res., August 1, 2000; 60(16): 4493 - 4498. [Abstract] [Full Text]